Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
|ClinicalTrials.gov Identifier: NCT00346008|
Recruitment Status : Completed
First Posted : June 29, 2006
Last Update Posted : May 30, 2013
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.
|Condition or disease||Intervention/treatment|
|Melanoma (Skin)||Genetic: mutation analysis Other: high performance liquid chromatography Other: laboratory biomarker analysis Other: questionnaire administration|
- Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
- Assess the feasibility of mutation detection using sequencing and HPLC.
- Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.
OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
|Study Type :||Observational|
|Estimated Enrollment :||2500 participants|
|Official Title:||Genetic Epidemiologic Studies of Melanoma in Iceland|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||February 2009|
- Feasibility to identify melanoma
- Feasibility to detect mutation
- Ability to create datasets
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00346008
|Iceland Genomics Corporation|
|Reykjavik, Iceland, 105|
|Study Chair:||Alisa Goldstein, PhD||National Cancer Institute (NCI)|